类风湿关节炎滑膜免疫表型与抗瓜氨酸化肽抗体:治疗反应及影像学预后关联
该前瞻性研究纳入123例类风湿关节炎患者(78例ACPA+),分析滑膜免疫表型与ACPA状态、治疗反应及骨侵蚀的关系。ACPA+患者滑膜CD19+ B细胞及CD3+、CD8+ T细胞浸润更高,淋巴聚集更显著且与血清CXCL13升高相关;CD19+ B细胞水平与随访时骨侵蚀相关,EULAR治疗反应与T细胞浸润相关,CD68+巨噬细胞和CD8+ T细胞可预测TNF抑制剂反应。
要点
- ACPA+ RA患者滑膜CD19+ B细胞、CD3+和CD8+ T细胞浸润显著高于ACPA-患者。
- ACPA+患者滑膜CD19+ B细胞淋巴聚集更显著,且与血清CXCL13水平升高相关。
- CD19+ B细胞浸润水平与随访时骨侵蚀相关,T细胞和巨噬细胞标志物与治疗反应相关。
核心结论
- ACPA+ RA患者滑膜B细胞浸润和淋巴聚集水平显著更高,尤其在未治疗患者中。
- ACPA+患者疾病进展中骨侵蚀更多,血清CXCL13水平更高。
- ACPA+ RA患者EULAR治疗反应与T细胞和巨噬细胞标志物水平升高相关。
研究设计与样本
- 前瞻性连续纳入RA患者,治疗前后进行临床和血清学评估,临床随访时进行影像学评估。
- 滑膜组织免疫染色检测B细胞(CD19)、T细胞(CD3、CD4、CD8)、巨噬细胞(CD68)和血管(因子VIII)标志物。
- 采用ELISA定量血清CXCL13,使用验证的半定量评分法分析滑膜免疫表型及淋巴聚集。
- 使用EULAR反应标准评估非生物或生物改善病情抗风湿药治疗反应。
主要发现
- 共纳入123例受试者,其中78例ACPA+。
- ACPA+ RA患者滑膜CD19+ B细胞及CD3+、CD8+ T细胞水平显著高于ACPA-患者(各P < 0.05)。
- 未治疗患者中CD19+ B细胞水平显著更高。
- 随访时有骨侵蚀的患者CD19+ B细胞浸润水平更高(P = 0.0128)。
- ACPA+患者CD19+ B细胞淋巴聚集水平显著更高(P < 0.05),且与血清CXCL13水平升高相关。
关键数值与推荐
- ACPA+组滑膜CD19+ B细胞、CD3+和CD8+ T细胞水平显著高于ACPA-组(各P < 0.05)。
- 随访有骨侵蚀者CD19+ B细胞浸润水平更高(P = 0.0128)。
- ACPA+组CD19+ B细胞淋巴聚集水平显著更高(P < 0.05)。
- EULAR反应与CD3+ T细胞浸润水平显著相关(P < 0.05)。
- CD68+巨噬细胞和CD8+ T细胞水平预测TNF抑制剂反应(P < 0.05)。
临床怎么用
- ACPA+ RA患者滑膜B细胞浸润和淋巴聚集更显著,提示B细胞靶向治疗可能获益。
- 滑膜CD19+ B细胞浸润水平与骨侵蚀相关,可作为影像学预后参考。
- 滑膜T细胞和巨噬细胞标志物可能辅助预测EULAR治疗反应及TNF抑制剂反应。
- 血清CXCL13升高与ACPA+患者淋巴聚集相关,或可作为无创监测指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Serum anti-citrullinated peptide antibodies (ACPAs) may be present before the development of rheumatoid arthritis (RA) and may be predictive of more severe, erosive disease. This study was undertaken to examine the synovial tissue immunophenotype according to ACPA status in patients with RA, as well as the response to treatment and erosion status. METHODS: Consecutive RA patients were prospectively recruited and underwent clinical and serologic assessments before and after treatment. Radiologic assessment was performed at the time of clinical follow-up. Synovial tissue was immunostained for specific markers of B cells (CD19), T cells (CD3, CD4, and CD8), macrophages (CD68), and blood vessels (factor VIII). Serum CXCL13 levels were quantified by enzyme-linked immunosorbent assay. Synovial tissue sections were analyzed for immunophenotype according to ACPA status, using a validated semiquantitative scoring method, and also analyzed for the presence of lymphoid aggregates. Response to treatment with nonbiologic or biologic disease-modifying antirheumatic drugs was assessed using the European League Against Rheumatism (EULAR) response criteria. RESULTS: In total, 123 subjects (78 ACPA+) were included. Compared to ACPA- RA patients, synovium from ACPA+ RA patients was characterized by significantly higher levels of CD19+ B cells and CD3+ and CD8+ T cells (each P < 0.05), and CD19+ B cell levels were significantly higher in patients who were naive to treatment. The CD19+ B cell infiltrate level was higher in patients with erosions at follow-up (P = 0.0128). Levels of lymphoid aggregates of CD19+ B cells were significantly higher in ACPA+ patients (P < 0.05), and this was associated with increased serum CXCL13 levels. The EULAR response was significantly associated with the level of CD3+ T cell infiltrates (P < 0.05), while CD68+ macrophage and CD8+ T cell levels were predictive of the response to tumor necrosis factor inhibitors (P < 0.05). CONCLUSION: The results of this prospective study demonstrate that the levels of synovial B cell infiltrates and lymphoid aggregates were significantly higher in ACPA+ RA patients, especially those who were naive to treatment. In addition, ACPA+ subjects developed more erosions during progression of the disease and had higher serum levels of CXCL13. The EULAR response to therapy in ACPA+ RA patients was associated with increased levels of T cell and macrophage markers.
引用
- Orr C, Najm A, Biniecka M, et al. Synovial Immunophenotype and Anti-Citrullinated Peptide Antibodies in Rheumatoid Arthritis Patients: Relationship to Treatment Response and Radiologic Prognosis. Arthritis Rheumatol. 2017. PMID: 28732135. doi:10.1002/art.40218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。